
Please try another search
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Kristina M. Burow | 49 | 2014 | Independent Director |
Jeffrey S. Flier | 74 | 2016 | Independent Director & Member of Scientific Advisory Board |
Joshua Reed | 49 | 2021 | Independent Director |
Barry S. Coller | - | - | Member of Scientific Advisory Board |
Joan Massague | 71 | - | Member of Scientific Advisory Board |
Daniel B. Rifkin | - | - | Member of Scientific Advisory Board |
Lynn Sakai | - | - | Member of Scientific Advisory Board |
Leonard I. Zon | - | - | Member of Scientific Advisory Board |
Scott L. Friedman | - | - | Member of Scientific Advisory Board |
Timothy A. Springer | 76 | 2012 | Member of Scientific Advisory Board |
Michael Gilman | 69 | 2013 | Independent Director & Member of Scientific Advisory Board |
David L. Hallal | 59 | 2017 | CEO & Chairman of the Board |
Shelia M. Violette | 64 | - | Member of Scientific Advisory Board |
Akshay K. Vaishnaw | 62 | 2014 | President of R&D, Member of Scientific Advisory Board and Director |
Srinivas Akkaraju | 57 | 2022 | Independent Director |
Richard Brudnick | 68 | 2023 | Independent Director |
Katie Peng | 54 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review